BRD4 inhibition has been demonstrated to directly improve anti-cancer (CAR) CD4+ and CD8+ T cell activity, for example by inducing cytotoxicity and reducing T cell exhaustion [185,186,187,188]. The gene discussed is CD8A; the disease is cancer.